A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Authors:
- Naval DaverNDNaval Daver
- Rita AssiRARita Assi
- Farhad RavandiFRFarhad Ravandi
- Guillermo Garcia-ManeroGGGuillermo Garcia-Manero
- Elias JabbourEJElias Jabbour
- Courtney D. DiNardoCDCourtney D. DiNardo
- Tapan M. KadiaTKTapan M. Kadia
- Jing NingJNJing Ning
- Graciela Nogueras-GonzalezGNGraciela Nogueras-Gonzalez
- Sherry PierceSPSherry Pierce
- Dan GombosDGDan Gombos
- Steven KornblauSKSteven Kornblau
- 1 October 2017
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (10) , S7-S8